AIRLINK 75.18 Increased By ▲ 0.33 (0.44%)
BOP 5.01 Increased By ▲ 0.03 (0.6%)
CNERGY 4.51 Increased By ▲ 0.02 (0.45%)
DFML 41.86 Increased By ▲ 1.86 (4.65%)
DGKC 86.75 Increased By ▲ 0.40 (0.46%)
FCCL 21.50 Increased By ▲ 0.14 (0.66%)
FFBL 33.80 Decreased By ▼ -0.05 (-0.15%)
FFL 9.74 Increased By ▲ 0.02 (0.21%)
GGL 10.51 Increased By ▲ 0.06 (0.57%)
HBL 114.50 Increased By ▲ 1.76 (1.56%)
HUBC 139.52 Increased By ▲ 2.08 (1.51%)
HUMNL 11.78 Increased By ▲ 0.36 (3.15%)
KEL 5.22 Decreased By ▼ -0.06 (-1.14%)
KOSM 4.67 Increased By ▲ 0.04 (0.86%)
MLCF 37.99 Increased By ▲ 0.19 (0.5%)
OGDC 139.26 Decreased By ▼ -0.24 (-0.17%)
PAEL 26.10 Increased By ▲ 0.49 (1.91%)
PIAA 22.20 Increased By ▲ 1.52 (7.35%)
PIBTL 6.85 Increased By ▲ 0.05 (0.74%)
PPL 123.67 Increased By ▲ 1.47 (1.2%)
PRL 26.96 Increased By ▲ 0.38 (1.43%)
PTC 14.00 Decreased By ▼ -0.05 (-0.36%)
SEARL 59.50 Increased By ▲ 0.52 (0.88%)
SNGP 68.72 Decreased By ▼ -0.23 (-0.33%)
SSGC 10.47 Increased By ▲ 0.17 (1.65%)
TELE 8.42 Increased By ▲ 0.04 (0.48%)
TPLP 11.25 Increased By ▲ 0.19 (1.72%)
TRG 64.18 Decreased By ▼ -0.01 (-0.02%)
UNITY 26.58 Increased By ▲ 0.03 (0.11%)
WTL 1.46 Increased By ▲ 0.01 (0.69%)
BR100 7,962 Increased By 125 (1.6%)
BR30 25,726 Increased By 274.4 (1.08%)
KSE100 76,092 Increased By 977 (1.3%)
KSE30 24,475 Increased By 361.4 (1.5%)

British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.

UK approves GSK Covid drug, appears effective against Omicron

"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK Chief Scientific Officer Hal Barron said.

GSK and Vir have been engineering so-called pseudoviruses that feature major coronavirus mutations across all suspicious variants that have emerged so far, and have run lab tests on their vulnerability to sotrovimab treatment.

Comments

Comments are closed.